Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07228364 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

A Phase 1 study of Autosomal Dominant Polycystic Kidney Disease, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
15
Study locations

NCT07228364 is a Phase 1 study of Autosomal Dominant Polycystic Kidney Disease that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 40 participants, below the 157-participant average among 9 other Autosomal Dominant Polycystic Kidney Disease trials with a reported enrollment target (75% lower). The trial reports 15 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07228364, a Phase 1 study of Autosomal Dominant Polycystic Kidney Disease, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
15
Study locations

Study Summary

A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).

Conditions Studied

Autosomal Dominant Polycystic Kidney Disease

Interventions

  • DRUG AZD1613 - Part A
  • DRUG Placebo - Part A
  • DRUG AZD1613 - Part B
  • DRUG Placebo - Part B

Study Locations (15)

Other

  • Research Site - Chengdu
  • Research Site - Hangzhou
  • Research Site - Nanjing
  • Research Site - Shanghai
  • Research Site - Wuhan
  • Research Site - Xiamen
  • Research Site - London

Florida

  • Research Site - Jacksonville
  • Research Site - Orlando

Alabama

  • Research Site - Birmingham

California

  • Research Site - Loma Linda

Kansas

  • Research Site - Lenexa

Maryland

  • Research Site - Baltimore

Minnesota

  • Research Site - Rochester

Texas

  • Research Site - San Antonio

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-11-10
Est. Completion 2027-01-04
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07228364

The ClinicalTrials.gov registry entry for NCT07228364 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 157-participant average among 9 other Autosomal Dominant Polycystic Kidney Disease trials with a reported enrollment target (75% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease appearing as the primary indexed condition, and to 4 interventions - of which AZD1613 - Part A is the first listed.

NCT07228364 reports 15 study locations spanning 8 distinct geographic areas - top geographies include Other, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT07228364 about?

NCT07228364 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease". A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).

What is the current status of trial NCT07228364?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-11-10. Estimated completion is 2027-01-04.

What conditions does trial NCT07228364 study?

This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease.

What interventions are being tested in trial NCT07228364?

The interventions under investigation include: AZD1613 - Part A (DRUG), Placebo - Part A (DRUG), AZD1613 - Part B (DRUG), Placebo - Part B (DRUG).

Who is sponsoring clinical trial NCT07228364?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07228364 being conducted?

This trial has 15 study locations across Alabama, California, Florida, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Autosomal Dominant Polycystic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Autosomal Dominant Polycystic Kidney Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.